Capital Advisors Ltd’s Vigil Neuroscience VIGL Stock Holding History

Capital Advisors Ltd’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	–	–	1653
2024 Q1	$0	Buy	+4	New	+$12	﹤0.01%	1562

Other funds holding VIGL

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Capital Advisors Ltd's VIGL Position: Q2 2024 in Review

Capital Advisors Ltd sold out of Vigil Neuroscience (VIGL) in Q2 2024, closing a stake of 4 shares.

Capital Advisors Ltd first reported a position in VIGL in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 58 funds tracked by Wall St. Rank hold VIGL as of Q2 2024.

Capital Advisors Ltd reported no remaining Vigil Neuroscience position as of Q2 2024 after selling out during the quarter.
Capital Advisors Ltd sold 4 Vigil Neuroscience shares in Q2 2024.
Capital Advisors Ltd first reported a position in Vigil Neuroscience in Q1 2024 and held it in 1 quarter.
Capital Advisors Ltd's Vigil Neuroscience position peaked at $0 in Q1 2024.
58 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.